Overview

ReNu Biologix is a regenerative medicine platform focused on delivering advanced, non-surgical treatment options for pain management and musculoskeletal conditions. The platform utilizes biologic therapies such as PRP and other regenerative modalities to improve patient outcomes while reducing reliance on traditional pharmaceutical interventions.

Investment Thesis

The healthcare system is undergoing a fundamental shift in the treatment of chronic pain. Increasing regulatory pressure, public awareness, and clinical scrutiny are driving a move away from opioid-based pain management toward safer, more sustainable alternatives.

At the same time, regenerative medicine remains highly fragmented, with inconsistent protocols, varying quality standards, and limited institutional infrastructure.

Barritus Capital is building ReNu Biologix to address this gap—creating a modern platform focused on evidence-based treatments, clinical standardization, and scalable delivery of regenerative therapies.

Value Creation Strategy

Barritus is focused on developing ReNu Biologix into a differentiated platform through:

• Standardization of treatment protocols to ensure consistency and clinical integrity
• Investment in compliance, safety, and regulatory alignment
• Development of a scalable clinic model that can be replicated across markets
• Integration of data collection and outcomes tracking to support evidence-based care
• Expansion of provider training and education to drive adoption

Growth Initiatives

• Expansion into broader pain management and orthopedic applications
• Development of strategic partnerships with physicians and specialty clinics
• Introduction of additional biologic and regenerative treatment offerings
• Direct-to-consumer marketing focused on non-surgical alternatives
• Geographic expansion through partnerships and de novo clinics